Back
Back
ATYR1923-C-004
Official Title
202207111
Study Details
The purpose of the study is to determine if 2 different doses of efzofitimod verses placebo given intravenously every 4 weeks can reduce steroid need in patients with pulmonary sarcoidosis, and subsequently improve quality of life.
Principal Investigator
Dr. Adam Anderson
IRB Number
202207111
Eligibility
1. Participants must be 18 to 75 years old
2. Participants must have had pulmonary sarcoidosis for at least 6 months and must currently have symptoms
Compensation is provided (contact the study team for compensation amount).
Volunteer Information
For more information about this study, contact Volunteer for Health at:
- 314.362.1000
- rprstaff@wustl.edu